Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer

Digestive and Liver Disease

Volumn 47, Issue 10, 2015, Pages 884-890

  Sefrioui, David ^a,b   Sarafan Vasseur, Nasrin ^a,b   Beaussire, Ludivine ^a,b,c,d   Baretti, Marina ^c   Gangloff, Alice ^a   Blanchard, France ^a   Clatot, Florian ^a,d   Sabourin, Jean Christophe ^a,b   Sesboüé, Richard ^a,b   Frebourg, Thierry ^a,b   Michel, Pierre ^a,b   Di Fiore, Frédéric ^a,b,d  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF ROUEN   (France)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d CENTRE HENRI BECQUEREL   (France)

Author keywords

Circulating tumour DNA; K ras mutation; Prognostic value; Ultrasensitive detection method

Indexed keywords

CIRCULATING TUMOR DNA; DNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHIP BASED DIGITAL POLYMERASE CHAIN REACTION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENDER; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MALE; METASTATIC COLORECTAL CANCER; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERITONEUM METASTASIS; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; WILD TYPE; AGED; BLOOD; COLORECTAL NEOPLASMS; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MORTALITY; MUTATION; ONCOGENE RAS; PATHOLOGY; PROCEDURES; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DNA, NEOPLASM; FEMALE; GENES, RAS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; PROGNOSIS; SURVIVAL RATE;

EID: 84942191793     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2015.05.023     Document Type: Article

References (29)

1. Simon R., Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nature Reviews Drug Discovery 2013, 12:358-369.
2. Van Schaeybroeck S., Allen W.L., Turkington R.C., et al. Implementing prognostic and predictive biomarkers in CRC clinical trials. Nature Reviews Clinical Oncology 2011, 8:222-232.
3. Schmoll H.-J., Stein A. Colorectal cancer in 2013: towards improved drugs, combinations and patient selection. Nature Reviews Clinical Oncology 2014, 11:79-80.
4. Lefebure B., Charbonnier F., Di Fiore F., et al. Prognostic value of circulating mutant DNA in unresectable metastatic colorectal cancer. Annals of Surgery 2010, 251:275-280.
5. Bettegowda C., Sausen M., Leary R.J., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Science Translational Medicine 2014, 6:224ra24.
6. Diaz L.A., Williams R.T., Wu J., et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012, 486:537-540.
7. Misale S., Yaeger R., Hobor S., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486:532-536.
8. Murtaza M., Dawson S.-J., Tsui D.W.Y., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013, 497:108-112.
9. Dawson S.-J., Tsui D.W.Y., Murtaza M., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. New England Journal of Medicine 2013, 368:1199-1209.
10. Higgins M.J., Jelovac D., Barnathan E., et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clinical Cancer Research 2012, 18:3462-3469.
11. McBride D.J., Orpana A.K., Sotiriou C., et al. Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes, Chromosomes and Cancer 2010, 49:1062-1069.
12. Leary R.J., Sausen M., Kinde I., et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Science Translational Medicine 2012, 4:162ra154.
13. Gevensleben H., Garcia-Murillas I., Graeser M.K., et al. Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clinical Cancer Research 2013, 19:3276-3284.
14. Tänzer M., Balluff B., Distler J., et al. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS ONE 2010, 5:e9061.
15. Leon S.A., Shapiro B., Sklaroff D.M., et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Research 1977, 37:646-650.
16. Schwarzenbach H., Stoehlmacher J., Pantel K., et al. Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Annals of the New York Academy of Sciences 2008, 1137:190-196.
17. Spindler K.L., Pallisgaard N., Vogelius I., et al. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clinical Cancer Research 2012, 18:1177-1185.
18. Diaz L.A., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. Journal of Clinical Oncology 2014, 32:579-586.
19. Crowley E., Di Nicolantonio F., Loupakis F., et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nature Reviews Clinical Oncology 2013, 10:472-484.
20. Thierry A.R., Mouliere F., El Messaoudi S., et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nature Medicine 2014, 20:430-435.
21. Vogelstein B., Kinzler K.W. Digital PCR. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:9236-9241.
22. Diehl F., Schmidt K., Choti M.A., et al. Circulating mutant DNA to assess tumor dynamics. Nature Medicine 2008, 14:985-990.
23. Bizouarn F. Clinical applications using digital PCR. Methods in Molecular Biology 2014, 1160:189-214.
24. Taly V., Pekin D., Benhaim L., et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clinical Chemistry 2013, 59:1722-1731.
25. Lamy A., Blanchard F., Le Pessot F., et al. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. Modern Pathology 2011, 24:1090-1100.
26. Spindler K.-L., Appelt A.L., Pallisgaard N., et al. Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer. International Journal of Cancer 2014, 135:2984-2991.
27. Dwivedi D.J., Toltl L.J., Swystun L.L., et al. Prognostic utility and characterization of cell-free DNA in patients with severe sepsis. Critical Care 2012, 16:R151.
28. Song H., Nan Y., Cheng X.W. Circulating cf-DNA: a promising, noninvasive tool for assessment of early cardio-metabolic risk. Atherosclerosis 2014, 233:307-309.
29. Cui M., Fan M., Jing R., et al. Cell-Free circulating DNA: a new biomarker for the acute coronary syndrome. Cardiology 2013, 124:76-84.